What is Brief History of Twist Bioscience Company?

Twist Bioscience Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

What is the history of Twist Bioscience?

Twist Bioscience, founded in 2013, revolutionized synthetic DNA production with its silicon-based platform. Headquartered in South San Francisco, California, the company aimed to make DNA synthesis faster, cheaper, and more scalable.

This innovative approach has positioned Twist Bioscience as a leader in high-throughput DNA synthesis, impacting fields from drug discovery to data storage.

Twist Bioscience's journey began with a vision to transform DNA manufacturing. Their proprietary silicon chip technology allows for the production of synthetic DNA at an unprecedented scale and cost-effectiveness. This has made them a key player in the rapidly growing synthetic biology market. Their product offerings, including synthetic genes and oligo pools, are essential for advancements in various life science applications. For a deeper understanding of their market position, consider a Twist Bioscience Porter's Five Forces Analysis.

The story of Twist Bioscience begins with a clear vision to revolutionize DNA synthesis. Founded in 2013, the company emerged from the collective expertise of its co-founders, aiming to address significant challenges in the biotechnology sector.

The Genesis of Twist Bioscience

Twist Bioscience was officially established in 2013 by a team of visionary scientists and engineers. The company's inception was driven by the founders' recognition of a critical bottleneck in the biotech industry: the slow, costly, and low-throughput nature of traditional DNA synthesis methods.

• Emily Leproust, CEO and co-founder, brought extensive expertise in chemistry and biochemistry, with a PhD from the University of Houston and prior experience at Agilent Technologies.
• Co-founders Bill Banyai and Bill Peck contributed deep knowledge in DNA synthesis, chemistry, and engineering, forming a multidisciplinary founding team.
• The core innovation was a proprietary silicon-based platform designed for rapid and cost-effective production of high-quality synthetic DNA at scale.
• This groundbreaking approach involved synthesizing DNA directly on a silicon chip, enabling the simultaneous production of millions of oligonucleotides.

The company's foundational strategy revolved around developing a proprietary silicon-based platform. This innovative technology was designed to overcome the limitations of traditional DNA synthesis, promising faster, cheaper, and higher-throughput production of synthetic DNA. The Twist Biosynthesis Platform, the company's first product, was launched in 2015, offering researchers a streamlined online portal for ordering custom DNA sequences. This marked a significant step in making synthetic DNA more accessible and efficient for scientific research and development. Understanding the Growth Strategy of Twist Bioscience provides further context to their early development.

Early investor confidence in Twist Bioscience's disruptive technology was evident from its rapid funding rounds. The company secured $9.1 million in Series A financing in February 2014, swiftly followed by a $26 million Series B round in May 2014, led by Tao Invest with participation from ARCH Venture Partners and Paladin Capital Group. By January 2016, Twist Bioscience had amassed a total of $133 million in equity funding, supplemented by an additional $20 million in debt facilities. Emily Leproust has often cited her upbringing in a family that owned a small contracting business as a significant influence on her entrepreneurial drive, instilling an early appreciation for business operations and sales.

Twist Bioscience SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The early growth of the company saw a swift progression from its initial concept to the commercialization of its products. Founded in 2013, the company introduced its first offering, the Twist Biosynthesis Platform, in 2015. This platform provided researchers with an online portal for ordering custom DNA sequences.

Early Product Launch and Adoption

In 2015, the company launched its Twist Biosynthesis Platform, enabling researchers to order custom DNA sequences online. Simultaneously, the Alpha Manufacturing Program began, offering synthetic DNA sequences up to 1.8 kb with a 20-business-day delivery time, utilizing a 10,000-well silicon-based platform. By January 2016, the company had already supplied 65 million base pairs of DNA to over 100 customers, indicating strong early market acceptance.

Significant Capital Infusion for Expansion

The company's expansion was significantly propelled by multiple funding rounds. Following its initial Series A and B rounds in 2014, substantial investments continued, including a $37 million Series C in June 2015 and a $61 million Series D in January 2016. By May 2018, a Series E round secured an additional $50 million. As of July 2025, the company has raised a cumulative total of $321 million across 11 funding rounds.

Operational Footprint Expansion and Market Growth

The company strategically expanded its operations beyond its South San Francisco headquarters. In January 2023, shipments commenced from its second manufacturing site, the 'Factory of the Future,' in Wilsonville, Oregon. This 110,000-square-foot facility is designed to double manufacturing capacity and support an assembly-line approach, facilitating future product introductions.

Industry Growth and Market Position

These growth initiatives have solidified the company's position as a key player in the rapidly expanding synthetic biology industry. The global synthetic biology market is projected to reach USD 24.58 billion in 2025 and is anticipated to grow to approximately USD 192.95 billion by 2034, reflecting a compound annual growth rate of 28.63% from 2025 to 2034. North America, where the company has a significant presence, is expected to lead this market, holding an estimated 42.3% share in 2025. Understanding the Marketing Strategy of Twist Bioscience provides further insight into its development.

Twist Bioscience PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The history of Twist Bioscience is marked by significant milestones and continuous innovation, alongside navigating notable challenges. The company's core strength lies in its proprietary silicon-based DNA synthesis platform, enabling efficient and cost-effective synthetic DNA production. Key developments include the launch of the Twist Biosynthesis Platform and the Alpha Manufacturing Program in 2015. Further expanding its capacity, the 'Factory of the Future' in Wilsonville, Oregon, opened in January 2023, doubling production capabilities. The company also introduced advanced solutions like the Twist High Throughput Unique Dual Index Adapter System.

Innovation is a driving force, evidenced by a robust patent portfolio with a significant focus on data science and machine learning, holding an 18% patent grant share as of July 2024. The company has forged major partnerships with leading pharmaceutical, biotech, and academic institutions globally, including a recent collaboration with Curio Genomics to enhance NGS workflows in agrigenomics.

Silicon-Based DNA Synthesis

The proprietary platform enables high-throughput and cost-effective manufacturing of synthetic DNA, a foundational innovation for the company's offerings.

Advanced Indexing Solutions

The Twist High Throughput Unique Dual Index Adapter System was introduced to facilitate multiplexing and sample batching, improving efficiency in research applications.

Biomolecule Data Storage Patents

In August 2024, the company secured a patent for a biomolecule-based data storage system, highlighting innovation in novel data archiving methods.

Variant Nucleic Acid Libraries

Patents granted in June 2024 for variant nucleic acid libraries, particularly for coronavirus, demonstrate a focus on critical areas of biological research and diagnostics.

Oligonucleotide Synthesis Methods

Patents related to methods of synthesizing oligonucleotides using tethered nucleotides, awarded in April 2024, showcase ongoing advancements in DNA synthesis techniques.

Strategic Partnerships

Collaborations with global pharmaceutical, biotech, and academic institutions, alongside a specific partnership with Curio Genomics, underscore the company's commitment to expanding its reach and impact.

The company has faced significant challenges, including a $22.5 million settlement with Agilent in February 2020 concerning trade secret allegations. A class-action lawsuit alleging fraud and accounting improprieties remains pending. Additionally, a short-seller report in November 2022 made allegations that the company refuted. Financially, the company reported a net loss of $208.7 million for fiscal year 2024, though it implemented a restructuring plan that reduced research and development expenses to $90.9 million in the same year.

Legal Settlements and Lawsuits

The company settled a lawsuit with Agilent for $22.5 million in 2020 and is currently involved in a pending class-action lawsuit related to alleged fraud and accounting improprieties.

Short-Seller Allegations

In November 2022, the company publicly refuted allegations made in a short-seller report, labeling them as 'misleading' and 'inaccurate.' This highlights the scrutiny faced by the company.

Financial Performance

The company reported a net loss of $208.7 million for fiscal year 2024, indicating financial pressures despite ongoing operational developments and strategic shifts.

Restructuring and R&D Expenses

A restructuring plan was implemented, leading to a decrease in research and development expenses to $90.9 million in fiscal year 2024, demonstrating a strategic adjustment to operational costs.

Strategic Spin-off

The spin-off of its DNA Data Storage initiative into Atlas Data Storage in May 2025, which secured $155 million in seed financing, allows the company to concentrate on its core life sciences business.

Focus on Core Business

This strategic move to spin off the DNA data storage initiative underscores the company's adaptability and commitment to optimizing its business model for market opportunities and operational efficiency.

Twist Bioscience Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The history of Twist Bioscience is marked by rapid growth and strategic expansion since its inception. The company's journey showcases a commitment to innovation in synthetic DNA technology, evolving from its early funding rounds to becoming a significant player in the biotech industry.

Financial Growth and Guidance

Twist Bioscience projects continued revenue growth, with total revenue guidance for fiscal year 2025 set between $372 million and $379 million. This represents an approximate 20% year-over-year increase.

Path to Profitability

The company anticipates adjusted EBITDA losses between $48 million and $53 million for fiscal 2025. However, a clear path to breakeven is projected by the end of fiscal 2026.

Market Expectations and Strategy

Analysts' stock price forecasts suggest an average of $70.24 for 2025. The company's strategy remains focused on innovation and customer impact to expand market share.

Long-Term Vision

Twist Bioscience continues to explore opportunities in digital data storage in DNA and biologics drug discovery. This aligns with the company's founding vision to empower biology engineering and drive positive global change, reflecting the Mission, Vision & Core Values of Twist Bioscience.

Twist Bioscience Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔